The U.S. Department of Health and Human Services announced on September 30 in Washington a set of initiatives designed to compress clinical development timelines by embedding AI and computational simulation into trial design — and by moving away from the sharply delineated Phase I/II/III structure that has governed drug development for decades.

The centerpiece is a five-year program called SURPASS, short for "Simulation-augmented, Real-time Platform Adaptive Seamless Trials." HHS will run it through the Advanced Research Projects Agency for Health (ARPA-H), the agency created to pursue high-risk, high-reward biomedical research outside conventional funding channels. The program will open for proposals later this fall.

According to the program's website, SURPASS will accept "ground-breaking ideas from cross-disciplinary teams in statistics, AI, and clinical trial design, operations, and regulation." That scope signals HHS wants more than incremental automation of existing trial workflows. The program targets three distinct competencies — statistical methodology, regulatory operations, and computational modeling — that research organizations currently staff and budget separately.

For R&D managers at pharma and biotech companies, the structural ambition matters more than the branding. "Seamless" trial designs collapse traditional phase boundaries into a single continuous protocol, and "platform" designs allow multiple candidates to share a common control arm and infrastructure. Both approaches have demonstrated cost and time savings in oncology and, prominently, during COVID-19 vaccine development. But regulators and sponsors have adopted them slowly, citing operational complexity and statistical hurdles in interim decision-making. SURPASS explicitly aims to make simulation and real-time adaptation standard tools for solving those problems.

What the announcement did not include is equally significant for planning purposes. HHS did not disclose the funding designated for the new initiatives. The agency also did not detail whether participants will receive additional flexibility or resources — an omission that leaves open questions about how the program will interact with FDA review expectations, indemnification, and data standards. R&D decision-makers evaluating whether to redirect biostatistics or clinical operations staff toward SURPASS proposals will need those figures before committing internal resources.

The announcement fits a broader federal push to apply AI across the drug development pipeline. For academic medical centers and contract research organizations, the program's interdisciplinary mandate suggests future solicitations will favor consortium-style bids that pair biostatistics departments with AI research groups and clinical operations teams, rather than single-discipline applications.

The program office is expected to publish funding amounts, solicitation deadlines, and participant terms as the fall launch approaches.